InfuSystem Holdings Files 8-K for Regulation FD Disclosure
Ticker: INFU · Form: 8-K · Filed: Sep 11, 2024 · CIK: 1337013
| Field | Detail |
|---|---|
| Company | Infusystem Holdings, INC (INFU) |
| Form Type | 8-K |
| Filed Date | Sep 11, 2024 |
| Risk Level | low |
| Pages | 2 |
| Reading Time | 2 min |
| Sentiment | neutral |
Sentiment: neutral
Topics: disclosure, regulation-fd
TL;DR
InfuSystem Holdings filed an 8-K for a Reg FD disclosure. No new material info disclosed.
AI Summary
InfuSystem Holdings, Inc. filed an 8-K on September 11, 2024, to report a Regulation FD Disclosure. The filing does not contain specific financial figures or material events beyond the disclosure itself.
Why It Matters
This filing indicates InfuSystem Holdings is making a public disclosure under Regulation FD, ensuring all investors receive the same material information simultaneously.
Risk Assessment
Risk Level: low — The filing is a standard procedural disclosure and does not contain information that would immediately impact the company's risk profile.
Key Players & Entities
- InfuSystem Holdings, Inc. (company) — Registrant
- September 11, 2024 (date) — Date of Report
- Regulation FD (regulation) — Disclosure Type
- Delaware (jurisdiction) — State of Incorporation
- Rochester Hills, Michigan (location) — Principal Executive Offices
FAQ
What is the purpose of this 8-K filing?
The purpose of this 8-K filing is to report a Regulation FD Disclosure.
What is the exact date of the earliest event reported in this filing?
The earliest event reported in this filing is dated September 11, 2024.
What is the company's principal executive office address?
The company's principal executive office is located at 3851 West Hamlin Road, Rochester Hills, Michigan 48309.
What is the Commission File Number for InfuSystem Holdings, Inc.?
The Commission File Number for InfuSystem Holdings, Inc. is 001-35020.
Under which section of the Securities Exchange Act is this report filed?
This report is filed pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934.
Filing Stats: 538 words · 2 min read · ~2 pages · Grade level 11.6 · Accepted 2024-09-11 06:58:43
Filing Documents
- infu-20240911.htm (8-K) — 28KB
- exhibit99109-11x2024chemom.htm (EX-99.1) — 28KB
- infusystem_safesmarttruste.jpg (GRAPHIC) — 760KB
- 0001628280-24-040073.txt ( ) — 1223KB
- infu-20240911.xsd (EX-101.SCH) — 2KB
- infu-20240911_lab.xml (EX-101.LAB) — 21KB
- infu-20240911_pre.xml (EX-101.PRE) — 12KB
- infu-20240911_htm.xml (XML) — 3KB
01 - Regulation FD Disclosure
Item 7.01 - Regulation FD Disclosure On September 11, 2024 , InfuSystem Holdings, Inc. (the "Company"), and its joint venture partner Sanara MedTech Inc. ("Sanara"), issued a press release announcing the execution of an exclusive United States distribution agreement, and minority investment, with ChemoMouthpiece, LLC. The press release is furnished as Exhibit 99.1 to this Current Report on Form 8-K. The information furnished in this Item 7.01 — "Regulation FD Disclosure" of this Current Report on Form 8-K and the press release attached hereto as Exhibit 99.1 shall not be deemed "filed" for the purpose of Section 18 of the Securities Exchange Act of 1934, as amended, or otherwise subject to the liabilities of such section, and shall not be deemed to be incorporated by reference into the filings of the Company under the Securities Act of 1933, as amended, or the Securities Exchange Act of 1934, as amended.
01 - Financial Statements and Exhibits
Item 9.01 - Financial Statements and Exhibits (d) Exhibits Exhibit No. Description 99.1 Press Release of InfuSystem Holdings, Inc. dated September 11 , 2024 104 Cover Page Interactive Data File (embedded within the Inline XBRL document) SIGNATURE Pursuant to the requirements of the Securities Exchange Act of 1934 the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. INFUSYSTEM HOLDINGS, INC. By: /s/ Barry Steele Barry Steele Chief Financial Officer Dated: September 11, 2024